Characteristics and Outcomes of Acute Myeloid Leukaemia Patients With Baseline CD7 Expression

Authors

Wei-Ying Jen
Koji Sasaki
Sanam Loghavi
Sa A Wang
Wei Qiao
Gautam Borthakur
Farhad Ravandi
Tapan M Kadia
Ghayas C Issa
Nicholas J Short
Musa Yilmaz
Naval G Daver
Courtney D DiNardo

Publication Date

6-1-2024

Journal

British Journal of Haematology

DOI

10.1111/bjh.19446

PMID

38603594

PMCID

PMC11770636

PubMedCentral® Posted Date

6-1-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Targeted therapy development for acute myeloid leukaemia (AML) requires an understanding of specific expression profiles. We collected flow cytometry data on 901 AML patients and recorded aberrant CD7 expression on leukaemic blasts. 263 (29.2%) had blasts positive for CD7. CD7+ AML was more likely to be adverse risk (64.6% vs. 55.6%, p = 0.0074) and less likely to be favourable risk (15.2% vs. 24.1%, p = 0.0074) by European LeukemiaNet 2022 criteria. Overall survival was inferior (11.9 [95% CI, 9.7-15.9] vs. 19.0 months [95% CI, 16.1-23.0], p = 0.0174). At relapse, 30.4% lost and 19.0% gained CD7, suggesting moderate instability over time.

Keywords

Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult, Antigens, CD7, Flow Cytometry, Immunophenotyping, Leukemia, Myeloid, Acute, Prognosis, AML, CD7, flow cytometry, cytomolecular characteristics

Published Open-Access

yes

Recommended Citation

Jen, Wei-Ying; Sasaki, Koji; Loghavi, Sanam; et al., "Characteristics and Outcomes of Acute Myeloid Leukaemia Patients With Baseline CD7 Expression" (2024). Faculty, Staff and Student Publications. 5543.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5543